Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 1 (JAK1), this compound shows promise in the development of treatments for autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its high selectivity for JAK1 over other JAK family members may reduce off-target effects and improve safety profiles in therapeutic applications. The compound is primarily investigated in preclinical studies to evaluate efficacy, pharmacokinetics, and mechanism of action in modulating cytokine signaling pathways involved in immune response regulation.